Liontrust Investment Partners’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $4.16M | Sell |
12,769
-6,111
| -32% | -$1.99M | 0.06% | 130 |
|
|
2025
Q1 | $5.1M | Buy |
18,880
+4,857
| +35% | +$1.31M | 0.08% | 122 |
|
|
2024
Q4 | $3.3M | Buy |
14,023
+8,940
| +176% | +$2.1M | 0.05% | 131 |
|
|
2024
Q3 | $1.24M | Hold |
5,083
| – | – | 0.02% | 162 |
|
|
2024
Q2 | $1.24M | Buy |
5,083
+4,933
| +3,289% | +$1.2M | 0.02% | 162 |
|
|
2024
Q1 | $22.4K | Sell |
150
-431
| -74% | -$64.4K | ﹤0.01% | 194 |
|
|
2023
Q4 | $111K | Sell |
581
-386
| -40% | -$73.9K | ﹤0.01% | 192 |
|
|
2023
Q3 | $171K | Sell |
967
-10,256
| -91% | -$1.82M | ﹤0.01% | 189 |
|
|
2023
Q2 | $2.13M | Sell |
11,223
-22,006
| -66% | -$4.18M | 0.03% | 176 |
|
|
2023
Q1 | $6.66M | Buy |
+33,229
| New | +$6.66M | 0.1% | 125 |
|
|
2022
Q4 | – | Sell |
-28,529
| Closed | -$5.71M | – | 187 |
|
|
2022
Q3 | $5.71M | Sell |
28,529
-5,100
| -15% | -$1.02M | 0.09% | 124 |
|
|
2022
Q2 | $4.9M | Buy |
+33,629
| New | +$4.9M | 0.07% | 149 |
|